Atheros

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Atheros

Quick Facts

Property Description
Active ingredient Clopidogrel (as bisulfate salt)
Form Oral film-coated tablet
Pharmacological class Antiplatelet Agent (Thienopyridine)
General purpose Prevention of unwanted blood clot formation (Prophylaxis)
Origin Synthetic compound

What is Atheros and What Class of Medicine is It?

Atheros is a prescription-only medicine containing the active ingredient Clopidogrel, which places it within the Antiplatelet agent pharmacological class. This synthetic compound belongs to the specific chemical group known as thienopyridine derivatives, confirming its classification as a P2Y12 inhibitor, a mechanism that distinguishes it from older antiplatelet drugs. Antiplatelet therapy, including the use of Clopidogrel, is clinically recognized as a standard approach for reducing serious vascular events among high-risk adult patients, supporting the drug's role in systemic prophylaxis.


Composition, Form, and Therapeutic Action

The preparation is a single-ingredient product delivered as an oral film-coated tablet, suitable for administration by the oral route. Its core composition features Clopidogrel, often used as the bisulfate salt, integrated with standard solid pharmaceutical excipients. Clopidogrel functions as a platelet aggregation inhibitor by selectively and irreversibly altering the P2Y12 ADP receptor on the surface of platelets. This action is designed to result in the reduction of thrombotic events in patients. This overall action is intended to reduce the capability of the blood to form unwanted clots (thrombi), thereby supporting the maintenance of adequate blood flow against atherothrombotic events.

What side effects are possible with Atheros?

Possible Side Effects and Safety Information

Atheros (Clopidogrel) is an antiplatelet agent whose official safety profile is primarily defined by the Hemorrhagic Risk Profile, meaning the potential for bleeding, which can range from common occurrences to serious events. Adverse reactions are classified according to the body system affected and their reported frequency in official regulatory documents.


Key Adverse Reactions by Frequency

The most common adverse effects (occurring in up to 1 in 10 patients) relate to bleeding and mild gastrointestinal issues. These include gastrointestinal haemorrhage, bruising (haematoma), epistaxis (nosebleeds), diarrhoea, and abdominal pain.

Uncommon reactions (up to 1 in 100 patients) may involve intracranial hemorrhage, headache, dizziness, nausea, and gastric or duodenal ulceration.

Very rare, but serious, adverse reactions documented in the labeling include Thrombotic Thrombocytopenic Purpura (TTP), acute liver failure, and aplastic anaemia, some of which may be fatal.


Safety Considerations and Restrictions

The risk of bleeding requires careful observation, especially during the first weeks of treatment. The medicine is formally contraindicated and must not be used in individuals with active pathological bleeding (such as a peptic ulcer or intracranial hemorrhage) or severe hepatic (liver) impairment.

Regulatory documents note caution is needed when using this medicine in patients with renal (kidney) impairment or moderate hepatic disease. Furthermore, the safety consequences of using Clopidogrel alongside other agents that increase bleeding risk, such as NSAIDs or oral anticoagulants, is a documented concern.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the overdose profile of Atheros (Clopidogrel) based on its primary antiplatelet effect. Overexposure to this medicine is documented to result in an extension of bleeding time and the potential development of bleeding complications. These complications carry the potential for severe or life-threatening outcomes.


Documented Overdose Manifestations

Clinical Finding Regulatory Status
Prolonged Bleeding Time Officially documented manifestation of overexposure.
Bleeding Complications Documented risk, with the potential for life-threatening or severe outcomes.

Emergency Action and Management

Due to the risk of severe bleeding, immediate emergency medical attention must be sought if overexposure or overdose is suspected. This required action is mandated by the potential severity of the consequences.

The regulatory profile notes that the drug's effect on platelets is irreversible, lasting for the life of the platelet, and no specific antidote is known to chemically reverse this effect. Management is focused on supportive care for the bleeding event.

  • Antidote Status: No specific antidote is known.
  • Supportive Measures: Platelet transfusion may be considered, based on biological plausibility, as a measure to restore clotting ability and manage complications.

Official documents define this profile by the necessity of urgent medical intervention due to the inherent risk of severe hemorrhage.

Therapeutic Uses of Atheros

Quick Facts

  • Primary Use: Supports the management of high cholesterol (hyperlipidemia).
  • Lipid Goals: Helps reduce low-density lipoprotein (LDL) cholesterol and triglycerides.
  • Secondary Use: May support a reduction in the probability of major cardiovascular events, such as heart attack and stroke.

Atheros is a prescription medication utilized in adult patients to support the management of certain lipid imbalances. Its primary therapeutic domains involve addressing elevated levels of LDL cholesterol and triglycerides in the bloodstream. This is a crucial component of overall cardiovascular health management when dietary changes alone have not sufficiently supported desired lipid levels.

By helping to lower undesirable blood lipid levels, Atheros may support a reduction in the probability of specific coronary events, including myocardial infarction (heart attack) and stroke, particularly in individuals with pre-existing risk factors. It is also indicated to manage lipid levels in patients diagnosed with familial hypercholesterolemia, a genetic disorder associated with very high cholesterol. The goal of this treatment is to maintain patient health and support a favorable long-term outlook.

Patients should use this medication as part of a comprehensive management strategy, which often includes diet, exercise, and other lifestyle modifications.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Atheros is for use in adult patients and pediatric patients 2 years and older for certain indications. However, governmental regulatory documents formally prohibit or strongly advise against its use in several specific populations and clinical conditions.

Classification Who Cannot Use / Restricted Use
Contraindicated Patients with known hypersensitivity to the drug or its excipients.
Contraindicated Pregnant women and breastfeeding women due to the potential for fetal harm and unknown risk to the nursing infant.
Avoid Use Patients with moderate or severe hepatic impairment.
Avoid Use Patients with severe renal impairment; safety and efficacy are not established in this group.
Restriction Concomitant use with strong CYP3A4 inducers (including St. John's wort) should be avoided or is contraindicated.
Restriction Not recommended for patients with a history of or current Interstitial Lung Disease (ILD) or related conditions.

Use in the overall pediatric population remains not established except for the specific age group and indication that has been formally approved.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official regulatory profile for Atheros is structured around medicines that can significantly alter the drug's concentration in the body or increase the risk of bleeding.

Pharmacokinetic Interactions (Drug Exposure)

The coadministration of Atheros with medicines that are combined inhibitors of P-glycoprotein (P-gp) and strong Cytochrome P450 3A (CYP3A) is generally avoided or restricted to specific patient populations. This combination can lead to a substantial increase in Atheros exposure, increasing the documented risk of bleeding. Similarly, combining Atheros with strong combined inducers of P-gp and CYP3A is generally avoided because these agents can significantly decrease Atheros exposure, which may reduce its intended effectiveness.

Pharmacodynamic Interactions (Risk of Bleeding)

Atheros must be used with caution when combined with other agents that affect blood clotting or platelet function. The concomitant use of Atheros with other anticoagulants, antiplatelet agents, or Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) increases the officially documented risk of major bleeding and requires close clinical monitoring. Agents such as SSRIs and SNRIs are also noted in the regulatory documents as potentially increasing bleeding risk.

Procedural Constraints

The regulatory documents provide specific, step-by-step instructions for safely transitioning a patient between Atheros and other types of oral or injectable anticoagulants, such as warfarin or unfractionated heparin, to ensure continuous treatment coverage and manage the risk of clotting or hemorrhage during the switch period.

Mechanism of Action

Atheros's action is defined by a precise, multi-step pharmacodynamic mechanism that acts exclusively on the machinery of the blood platelet, resulting in a systemic decrease in platelet aggregation potential.

Irreversible Platelet Receptor Blockade

The drug's core action involves a permanent chemical modification of the platelet's primary activation site, the P2Y12 receptor. Clopidogrel is an inactive prodrug that requires metabolic conversion by liver enzymes, notably CYP2C19, into an active metabolite. This metabolite then forms an irreversible covalent bond with the P2Y12 receptor, permanently disabling it and preventing the binding of the natural activator, ADP. This specific mechanism determines that the inhibition persists for the lifespan of the affected platelet.

Modulation of Intracellular Signaling

Blocking the P2Y12 receptor prevents it from suppressing the enzyme Adenylyl Cyclase via the Gi protein pathway. The resulting sustained or elevated level of the internal inhibitory messenger, Cyclic AMP ( cAMP), effectively modulates the platelet's internal signaling cascade. This intracellular modulation restricts the platelet's ability to activate the final common aggregation receptor, GPIIb/ IIIa.

Constraint on Systemic Thrombotic Potential

The combined effect of P2Y12 blockade and cAMP-mediated inhibition results in a sustained inhibition of platelet aggregation. This physiological consequence leads to a decrease in the blood's capacity for thrombus formation throughout the vascular system. The mechanism's effectiveness is constrained by the efficiency of the CYP2C19 enzyme, as genetic variations in its activity can limit the amount of active drug available to block the target receptor.

Dosage and Administration Information

Atheros (Clopidogrel) is an antiplatelet medicine administered exclusively by the oral route as a film-coated tablet. The administration is based on a once-daily schedule, which should be maintained at a consistent time each day. Instructions indicate the medicine can be taken with or without food.


Official Administration Guidelines

Instruction Domain Detail
Route of administration Oral
Standard Adult Dose 75 mg once daily (Maintenance)
Loading Dose (ACS) Single 300 mg oral dose
Timing in relation to meals With or without food

For long-term management, the standard regimen is the 75 mg maintenance dose. For patients with Acute Coronary Syndrome (ACS), treatment is initiated with a single 300 mg loading dose followed by the daily 75 mg dose. This medicine is administered as part of a combination regimen with aspirin (Acetylsalicylic Acid) in most acute settings. Specific modifications exist for certain populations: the 300 mg loading dose is generally omitted for medically managed STEMI patients who are 75 years of age or older.

If a dose is missed, the protocol is based on the time elapsed. If the scheduled dose is missed by less than 12 hours, it should be taken immediately. If the dose is missed by more than 12 hours, the instruction is to skip the missed dose and resume the normal once-daily schedule with the next planned tablet, without taking a double dose. Standard protocols involve discontinuing the medicine 7 days prior to elective major surgery.

Recent Clinical Evidence

Atheros: Recent Clinical Evidence

Phase III Clinical Program

Initial research has explored how the investigational agent, Atheros, could potentially influence the management of chronic inflammatory conditions, focusing primarily on individuals with Moderate-to-Severe Psoriatic Arthritis (PsA). These participants had previously received, but had an inadequate response to, conventional disease-modifying antirheumatic drugs (DMARDs).


Study Design and Outcomes

The core research involved two multinational, randomized, double-blind, placebo-controlled trials. Key participants were adults (age 18–75) diagnosed with active PsA. Specific populations, such as individuals with active infections or pregnant individuals, were excluded from these studies.

Studies evaluated whether the agent could influence the signs and symptoms of PsA, including measures of joint tenderness and swelling.

  • Joint Symptoms: In both trials, subjects receiving Atheros at specified study dosages reported changes in the proportion of participants achieving ACR20 response (a standard measure of at least 20% improvement in PsA criteria) compared to the placebo group.
  • Skin Lesions: A secondary outcome for individuals with significant psoriasis skin involvement was the change in PASI 75 score (a 75% improvement in Psoriasis Area and Severity Index). Studies reported changes in the proportion of participants achieving PASI 75.

Comparison and Safety

One study compared the reported effects on pain relief and disease activity for Atheros versus an established biologic agent. The research examined the difference in the proportion of participants achieving the higher thresholds of ACR50 and ACR70 responses between the investigational agent and the active control group. In that study, findings were reported as similar between the two groups, but direct statistical comparison for superiority was not the primary goal.

Extended studies evaluated whether the agent was associated with changes in major joint damage progression over a one-year period. Tolerability data were collected during the study.

Key Studies & References

  1. Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
  2. Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

Frequently Asked Questions (FAQ)

Common questions about Atheros (FAQ)

Q: Are there any major diet restrictions while using Atheros?

Official product information notes that certain foods may interfere with how Atheros works in the body. Specifically, the co-consumption of grapefruit or grapefruit juice may potentially reduce the drug’s intended effectiveness. The official documentation does not commonly list other major dietary restrictions.

Q: Is there a generic version of Atheros available?

Atheros contains the active ingredient Clopidogrel. According to regulatory authorities, the generic equivalent, Clopidogrel, is widely available as a prescription medicine. Both the brand name and generic versions are subject to the same regulatory approval processes.

Q: Can Atheros affect sleep patterns?

Yes, official safety data indicates that this medicine may affect sleep. Regulatory documents list insomnia, meaning difficulty sleeping, as an uncommon side effect, meaning it has been reported in up to 1 in 100 patients.

Q: Is it true that Atheros is a Schedule [X] drug?

No. Official regulatory bodies classify Atheros (Clopidogrel) as a prescription-only medicine in all major regulatory regions and is not classified as a controlled substance or scheduled drug.

Q: What is the connection between Atheros and [Specific Medical Test]?

Official information emphasizes the importance of monitoring for potential bleeding issues while taking this medication. If symptoms suggestive of bleeding are noted, official information indicates that prompt blood cell count determinations and other appropriate testing may be necessary.

Q: Can Atheros be stopped suddenly or does it require tapering?

Regulatory documents provide guidance for stopping the medicine only in specific contexts, such as requiring its discontinuation 7 days prior to elective major surgery. Because discontinuing antiplatelet therapy may increase risk, the decision to stop or change the medicine requires the guidance of a healthcare professional.

Q: Does Atheros cause weight gain or loss?

Regulatory safety information for Clopidogrel (Atheros) does not list weight gain or weight loss among the documented common, uncommon, or rare side effects reported in official documents.

Q: Is it safe to drive after taking Atheros?

Official product information states that Atheros has no or negligible influence on a person’s ability to drive or use machines. Official information indicates that the medicine is not expected to impair driving ability.

Q: Is the medication Atheros used in other countries?

Yes, the active ingredient in Atheros, Clopidogrel, is recognized globally. It has received regulatory approval and is used under various brand names in many countries, with official product information published by multiple international bodies.

Q: Does Atheros affect blood sugar levels?

Regulatory safety information for Clopidogrel (Atheros) does not list effects on blood sugar or glucose metabolism among the documented adverse reactions reported in official documents.

Q: Is there a link between Atheros and mood changes?

Regulatory documents list depression as an effect that has been commonly reported (up to 1 in 10 patients). In addition, post-marketing experience has included reports of confusion and hallucinations.

Q: What kind of tests are required before someone can start Atheros?

While regulatory documents do not mandate routine pre-treatment tests, the drug is formally contraindicated (advised against) in patients with conditions like active pathological bleeding or severe hepatic (liver) impairment. The assessment for these and other important conditions is generally performed by a healthcare professional prior to starting the medicine.

Q: Does the color or shape of the Atheros pill have a meaning?

Official regulatory documents describe the tablet as having a specific shape (e.g., capsule-shaped) and colour (e.g., light pink). These attributes are primarily used by manufacturers and pharmacists for the purpose of product identification and tracking.

Q: Can Atheros be taken by someone who doesn't have the main condition it treats?

Regulatory bodies specify that Atheros is formally indicated, or approved, for the secondary prevention of atherothrombotic events (unwanted blood clots) in adults who have already experienced conditions like a myocardial infarction, ischemic stroke, or peripheral arterial disease. This is the only officially approved purpose.

Q: Is it true that Atheros can help with other health issues?

The official regulatory approval for Atheros is for its antiplatelet effect, which prevents blood clots. Although there may be research themes related to other conditions, such as inflammatory diseases like Psoriatic Arthritis, these are typically investigational and are not part of the current approved therapeutic indications.

Q: Does Atheros contain [common allergen, e.g., lactose or gluten]?

Official product information indicates that Atheros tablets commonly contain lactose as an inactive ingredient, or excipient. Official documents state that patients with rare hereditary problems such as galactose intolerance or glucose-galactose malabsorption should not use the medicine.

Q: Can Atheros cause skin sensitivity or rashes?

Yes. Regulatory documents list rash and itching as common side effects, meaning they occur in up to 1 in 10 patients. Furthermore, more serious reactions, such as angioedema (swelling beneath the skin), are also documented in official safety information.

Q: How quickly is Atheros supposed to start working?

The antiplatelet effect of a standard 75 mg daily dose generally reaches its full steady state between Day 3 and Day 7 of treatment. If a healthcare professional requires the effect more rapidly, a larger initial 'loading dose' is used, which achieves substantial platelet inhibition within 2 to 6 hours.

Q: Does Atheros interact with vitamins or herbal supplements?

Official information notes a caution against the concomitant use of Atheros with certain herbal supplements. Specifically, St. John's wort (a known CYP3A4 inducer) is noted as potentially decreasing the drug’s exposure in the body, which could reduce its intended effectiveness.

Q: Can Atheros be taken at the same time as [Common OTC Drug]?

Official regulatory documents specifically discourage the use of Atheros with certain medications, including some Proton Pump Inhibitors (PPIs) like omeprazole. This combination may reduce the active drug’s exposure, which is associated with a reduction in therapeutic effect.

Q: Is it normal to feel [mild, non-specific side effect, e.g., slightly tired] when starting Atheros?

Yes, common side effects (up to 1 in 10 patients) documented in regulatory information include feelings such as headache, dizziness, and fatigue. These are commonly reported during treatment.

Q: Can Atheros be split or crushed?

Atheros is supplied as a film-coated tablet. If the official product information does not explicitly instruct that the tablet can be broken or split (i.e., if it is not scored), official information indicates that generally, patients should not split or crush the tablet unless explicitly instructed by the label.

How should Atheros be stored and disposed of?

How to Store and Dispose of Atheros (Clopidogrel)

Clopidogrel tablets must be stored according to official regulatory specifications to maintain product integrity and safety.

Storage Requirements

Storage Component Official Requirement
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C.
Protection Keep away from excess heat and moisture.
Container Keep the medicine in its original container, tightly closed.
Child Safety Must be stored out of the sight and reach of children.

Storage conditions are designed to maintain stability until the labeled expiration date, prohibiting exposure to freezing temperatures.

Disposal

Unused or expired Atheros must be disposed of according to local regulations, which may involve take-back programs or specific instructions from a pharmacist. The substance must not be allowed to enter drains or wastewater systems due to documented environmental toxicity.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Atheros found in:

A-Z Index: